Additional file 2 of Activation of the chemokine receptor 3 pathway leads to a better response to immune checkpoint inhibitors in patients with metastatic urothelial carcinoma

Additional file 2: Figure S2. Validation of relationship between CXCR3 pathway activation and efficacy of ICIs in cancer patients. A–F The differences in the proportions of mUC patients with different responses to ICIs between CXCR3-high and CXCR3-low patients in the other six ICI cohorts. Light blue color represents the responders; dark blue color represents the non-responders. G–L The differences in activation of the CXCR3 pathway in CXCR3-high and CXCR3-low patients from the other six ICI cohorts. NR no response, R response.